{"id":48997,"date":"2025-11-25T20:28:02","date_gmt":"2025-11-25T12:28:02","guid":{"rendered":"https:\/\/flcube.com\/?p=48997"},"modified":"2025-11-25T20:28:03","modified_gmt":"2025-11-25T12:28:03","slug":"novo-nordisks-semaglutite-alzheimers-failure-sends-stock-to-4-year-low","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48997","title":{"rendered":"Novo Nordisk&#8217;s Semaglutite Alzheimer&#8217;s Failure Sends Stock to 4-Year Low"},"content":{"rendered":"\n<p><strong>Novo Nordisk A\/S<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVO:NYSE\">NYSE: NVO<\/a>) announced that <strong>semaglutide<\/strong> failed to slow disease progression in two Phase\u202fIII <strong>Alzheimer&#8217;s disease trials<\/strong>, with no statistically significant difference observed between treated and placebo groups, prompting the company to discontinue planned one\u2011year extension studies and causing shares to plunge <strong>5.8%<\/strong> to their lowest level in four years.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-trial-failure-summary\">Trial Failure Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug<\/strong><\/td><td>Semaglutide (GLP\u20111 receptor agonist)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Novo Nordisk (NYSE: NVO)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Alzheimer\u2019s disease progression<\/td><\/tr><tr><td><strong>Trial Design<\/strong><\/td><td>Two Phase\u202fIII studies (double\u2011blind, placebo\u2011controlled)<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Slowing of cognitive decline (CDR\u2011SB, ADAS\u2011Cog)<\/td><\/tr><tr><td><strong>Result<\/strong><\/td><td>No significant slowing vs. placebo; trials terminated<\/td><\/tr><tr><td><strong>Extension Plans<\/strong><\/td><td>One\u2011year extension discontinued<\/td><\/tr><tr><td><strong>Stock Impact<\/strong><\/td><td>\u20135.8% to 4\u2011year low; ~$35\u202fbillion market cap erosion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-background-amp-strategic-context\">Drug Background &amp; Strategic Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> GLP\u20111 mimetic proven effective for obesity, cardiovascular risk reduction, and liver disease; hypothesized neuroprotective effects failed to translate in Alzheimer\u2019s<\/li>\n\n\n\n<li><strong>Market Position:<\/strong> Novo Nordisk lost the <strong>obesity market leadership<\/strong> to Eli Lilly\u2019s Zepbound earlier in 2025; Alzheimer\u2019s was viewed as a critical diversification opportunity<\/li>\n\n\n\n<li><strong>Analyst Expectations:<\/strong> Consensus had priced in <strong>15\u201120% probability<\/strong> of Alzheimer\u2019s success; failure removes a potential $10\u201115\u202fbillion revenue stream by 2035<\/li>\n\n\n\n<li><strong>Pipeline Implications:<\/strong> Company will shift resources to <strong>NASH and cardiovascular<\/strong> programs; <strong>amyloid\u2011beta<\/strong> and <strong>tau<\/strong> assets remain in early phases<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Alzheimer\u2019s Market Size (Global)<\/strong><\/td><td>$6.5\u202fbillion (2024)<\/td><\/tr><tr><td><strong>Semaglutide Peak Sales Forecast (Alzheimer\u2019s)<\/strong><\/td><td>$0 (removed from model)<\/td><\/tr><tr><td><strong>Novo Nordisk 2025E Revenue<\/strong><\/td><td>Downgrade of <strong>2\u20113%<\/strong> by sell\u2011side analysts<\/td><\/tr><tr><td><strong>Eli Lilly Competitive Gain<\/strong><\/td><td>+3.2% stock surge on Novo\u2019s news<\/td><\/tr><tr><td><strong>Next Catalyst<\/strong><\/td><td>Phase\u202fII NASH data <strong>Q1\u202f2026<\/strong>; oral semaglutide CV outcomes <strong>Q3\u202f2026<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Investor Sentiment:<\/strong> The failure compounds concerns about Novo\u2019s reliance on GLP\u20111 and its ability to innovate beyond metabolic disease<\/li>\n\n\n\n<li><strong>Credit Impact:<\/strong> S&amp;P placed Novo on <strong>negative outlook<\/strong> due to reduced diversification and higher R&amp;D risk profile<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Novo Nordisk\u2019s pipeline strategy, financial impact, and competitive position. Actual results may differ materially due to risks including regulatory changes, competitive dynamics, and clinical trial outcomes in other therapeutic areas.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk A\/S (NYSE: NVO) announced that semaglutide failed to slow disease progression in two&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48999,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,148,860],"class_list":["post-48997","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-results","tag-novo-nordisk","tag-nyse-nvo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novo Nordisk&#039;s Semaglutite Alzheimer&#039;s Failure Sends Stock to 4-Year Low - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novo Nordisk A\/S (NYSE: NVO) announced that semaglutide failed to slow disease progression in two Phase\u202fIII Alzheimer&#039;s disease trials, with no statistically significant difference observed between treated and placebo groups, prompting the company to discontinue planned one\u2011year extension studies and causing shares to plunge 5.8% to their lowest level in four years.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48997\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk&#039;s Semaglutite Alzheimer&#039;s Failure Sends Stock to 4-Year Low\" \/>\n<meta property=\"og:description\" content=\"Novo Nordisk A\/S (NYSE: NVO) announced that semaglutide failed to slow disease progression in two Phase\u202fIII Alzheimer&#039;s disease trials, with no statistically significant difference observed between treated and placebo groups, prompting the company to discontinue planned one\u2011year extension studies and causing shares to plunge 5.8% to their lowest level in four years.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48997\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-25T12:28:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-25T12:28:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2505.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48997#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48997\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo Nordisk&#8217;s Semaglutite Alzheimer&#8217;s Failure Sends Stock to 4-Year Low\",\"datePublished\":\"2025-11-25T12:28:02+00:00\",\"dateModified\":\"2025-11-25T12:28:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48997\"},\"wordCount\":360,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48997#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2505.webp\",\"keywords\":[\"Clinical trial results\",\"Novo Nordisk\",\"NYSE: NVO\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48997#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48997\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48997\",\"name\":\"Novo Nordisk's Semaglutite Alzheimer's Failure Sends Stock to 4-Year Low - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48997#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48997#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2505.webp\",\"datePublished\":\"2025-11-25T12:28:02+00:00\",\"dateModified\":\"2025-11-25T12:28:03+00:00\",\"description\":\"Novo Nordisk A\\\/S (NYSE: NVO) announced that semaglutide failed to slow disease progression in two Phase\u202fIII Alzheimer's disease trials, with no statistically significant difference observed between treated and placebo groups, prompting the company to discontinue planned one\u2011year extension studies and causing shares to plunge 5.8% to their lowest level in four years.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48997#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48997\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48997#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2505.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2505.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novo Nordisk's Semaglutite Alzheimer's Failure Sends Stock to 4-Year Low\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48997#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk&#8217;s Semaglutite Alzheimer&#8217;s Failure Sends Stock to 4-Year Low\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk's Semaglutite Alzheimer's Failure Sends Stock to 4-Year Low - Insight, China&#039;s Pharmaceutical Industry","description":"Novo Nordisk A\/S (NYSE: NVO) announced that semaglutide failed to slow disease progression in two Phase\u202fIII Alzheimer's disease trials, with no statistically significant difference observed between treated and placebo groups, prompting the company to discontinue planned one\u2011year extension studies and causing shares to plunge 5.8% to their lowest level in four years.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48997","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk's Semaglutite Alzheimer's Failure Sends Stock to 4-Year Low","og_description":"Novo Nordisk A\/S (NYSE: NVO) announced that semaglutide failed to slow disease progression in two Phase\u202fIII Alzheimer's disease trials, with no statistically significant difference observed between treated and placebo groups, prompting the company to discontinue planned one\u2011year extension studies and causing shares to plunge 5.8% to their lowest level in four years.","og_url":"https:\/\/flcube.com\/?p=48997","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-25T12:28:02+00:00","article_modified_time":"2025-11-25T12:28:03+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2505.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48997#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48997"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo Nordisk&#8217;s Semaglutite Alzheimer&#8217;s Failure Sends Stock to 4-Year Low","datePublished":"2025-11-25T12:28:02+00:00","dateModified":"2025-11-25T12:28:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48997"},"wordCount":360,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48997#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2505.webp","keywords":["Clinical trial results","Novo Nordisk","NYSE: NVO"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48997#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48997","url":"https:\/\/flcube.com\/?p=48997","name":"Novo Nordisk's Semaglutite Alzheimer's Failure Sends Stock to 4-Year Low - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48997#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48997#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2505.webp","datePublished":"2025-11-25T12:28:02+00:00","dateModified":"2025-11-25T12:28:03+00:00","description":"Novo Nordisk A\/S (NYSE: NVO) announced that semaglutide failed to slow disease progression in two Phase\u202fIII Alzheimer's disease trials, with no statistically significant difference observed between treated and placebo groups, prompting the company to discontinue planned one\u2011year extension studies and causing shares to plunge 5.8% to their lowest level in four years.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48997#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48997"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48997#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2505.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2505.webp","width":1080,"height":608,"caption":"Novo Nordisk's Semaglutite Alzheimer's Failure Sends Stock to 4-Year Low"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48997#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk&#8217;s Semaglutite Alzheimer&#8217;s Failure Sends Stock to 4-Year Low"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2505.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48997","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48997"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48997\/revisions"}],"predecessor-version":[{"id":49000,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48997\/revisions\/49000"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48999"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48997"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48997"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48997"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}